huANGPTL3/huPCSK9 Mouse
Product Name
huANGPTL3/huPCSK9 Mouse
Product ID
C002108
Strain Name
C57BL/6Cya-Angptl3em1(hANGPTL3)Pcsk9tm1(hPCSK9)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huANGPTL3/huPCSK9 Mouse (Catalog C002108) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Gene Name
PCSK9 & ANGPTL3
Gene Alias
FH3, PC9, FHCL3, NARC1, LDLCQ1, NARC-1, HCHOLA3, ANL3, ANG-5, FHBL2, ANGPT5
NCBI ID
Chromosome
Chr 1 (Human), Chr 1 (Human)
MGI ID
Datasheet
Strain Description
Angiopoietin‑like protein 3 (ANGPTL3) is mainly expressed in the liver and is a secreted glycoprotein structurally related to angiopoietins. The mature form of human ANGPTL3 protein contains an N‑terminal coiled‑coil domain and a C‑terminal fibrinogen‑like (FBN) domain. Through binding of its FBN‑like domain to integrin αvβ3, ANGPTL3 induces endothelial cell adhesion and migration, thereby playing a role in the regulation of angiogenesis [1]. In addition, ANGPTL3 can directly inhibit lipoprotein lipase (LPL) and endothelial lipase (EL), which are closely involved in the hydrolysis of circulating triglycerides (TG) and high‑density lipoprotein cholesterol (HDL‑C), respectively, thereby elevating circulating TG levels and affecting HDL levels [2-3]. In humans, ANGPTL3 is an important factor for HDL levels, and its plasma level is positively correlated with HDL‑C. Loss‑of‑function mutations in the ANGPTL3 gene (especially homozygous or compound heterozygous) lead to familial combined hypolipidemia (FHBL2) [4]. Furthermore, ANGPTL3 also plays important roles in biological and pathological processes related to lipid metabolism and angiogenesis, such as atherosclerosis, tumors, nephrotic syndrome, diabetes, and liver disease [3].
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease produced predominantly in the liver and also expressed in the intestine, heart, pancreas, renal interstitial cells, and neurons. The N-terminal and catalytic domains of PCSK9 are involved in protein maturation and stability, while the C-terminal domain plays a critical role in LDLR degradation [5]. PCSK9 is closely involved in the regulation of blood cholesterol. The low‑density lipoprotein receptor (LDLR) is a receptor responsible for clearing low‑density lipoprotein cholesterol (LDL‑C); PCSK9 binds to the EGF-A domain of cell-surface LDLR, promoting its endocytosis and lysosomal degradation, thereby reducing LDLR levels and elevating plasma LDL-C. Overexpression or gain‑of‑function mutations of the PCSK9 gene reduce LDLR levels, resulting in LDL‑C accumulation, hypercholesterolemia, and increased risks of cardiovascular diseases such as atherosclerosis and coronary heart disease, as well as neurodegenerative disorders including stroke and Alzheimer's disease [6].
The huANGPTL3/huPCSK9 mouse is a dual humanized model generated by gene editing on the huPCSK9 mouse (Catalog No.: C001617) background, in which the mouse Angptl3 endogenous region from the p.S17 to downstream of Exon 7 was replaced with the human ANGPTL3 region from p.S17 to downstream of Exon 7. The murine signal peptide was retained. This model is applicable to mechanistic studies of metabolic diseases, such as hypertriglyceridemia, hypercholesterolemia, and dyslipidemia, and is also suitable for the screening, development, and preclinical evaluation of dual-targeting drugs against ANGPTL3 and PCSK9.
Reference
Camenisch G, Pisabarro MT, Sherman D, et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin αvβ3 and induces blood vessel formation in vivo. J Biol Chem. 2002;277(19):17281-17290.
Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007;27(2):366-372.
Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13(12):731-744.
Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, Fennell T, Banks E, Ambrogio L, Cibulskis K, Kernytsky A, Gonzalez E, Rudzicz N, Engert JC, DePristo MA, Daly MJ, Cohen JC, Hobbs HH, Altshuler D, Schonfeld G, Gabriel SB, Yue P, Kathiresan S. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010 Dec 2;363(23):2220-7.
Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: The role of PCSK9. Arch Biochem Biophys. 2017 Jul 1;625-626:39-53.
Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014 Mar 14;114(6):1022-36.
Strain Strategy
The mouse Angptl3 endogenous region from p.S17 to downstream of Exon 7 of huPCSK9 mice (Catalog No.: C001617) was replaced with the human ANGPTL3 region from p.S17 to downstream of Exon 7. The murine signal peptide was retained.
Figure 1. Gene editing strategy of huPCSK9 mice. The mouse Pcsk9 gene sequence was replaced with the corresponding sequences in the human PCSK9 gene, including the UTR regions.
Figure 2. Gene editing strategy of huANGPTL3/huPCSK9 mice.
Application Area
Mechanistic studies of metabolic diseases, such as hypertriglyceridemia, hypercholesterolemia, and dyslipidemia;
Screening, development, and preclinical evaluation of dual‑targeting drugs against ANGPTL3 and PCSK9.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.